Diversion of Buprenorphine/Naloxone Coformulated Tablets in a Region with High Prescribing Prevalence

ABSTRACT The purpose of this article was to characterize practices of buprenorphine/naloxone (B/N) diversion in a region with a high prescribing prevalence. A cross-sectional, open-ended survey was administered to individuals entering opioid addiction treatment programs in two New England states. The authors obtained formative information about the knowledge, attitudes, beliefs, practices, and street economy of B/N diversion. The authors interviewed 51 individuals, 49 of which were aware of B/N medication. Of that number, 100% had diverted B/N to modulate opiate withdrawal symptoms arising from attempted “self-detoxification,” insufficient funds to purchase preferred illicit opioids, or inability to find a preferred source of drugs. Thirty of 49 (61%) participants obtained the illicit drug from an individual holding a legitimate prescription for B/N. A high proportion of individuals in the study locations who sought treatment for opioid addiction self-reported the purchase and use of diverted B/N. The diversion of B/N may be minimized by modifying educational, treatment, monitoring, and dispensing practices.

[1]  P. O'Connor,et al.  Clinical practice. Office-based treatment of opioid-dependent patients. , 2002, The New England journal of medicine.

[2]  M. Stitzer,et al.  Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. , 1995, Drug and alcohol dependence.

[3]  K. Preston,et al.  Clinical pharmacology of buprenorphine: Ceiling effects at high doses , 1994, Clinical pharmacology and therapeutics.

[4]  A. Cowan,et al.  Buprenorphine: a unique drug with complex pharmacology. , 2004, Current neuropharmacology.

[5]  E. Vuori,et al.  Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. , 2007, Drug and alcohol dependence.

[6]  M. Carrieri,et al.  The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. , 2008, Addiction.

[7]  G. Badger,et al.  Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens. , 2001, Addiction.

[8]  Katherine B. Morton,et al.  Results from the 2008 National Survey on Drug Use and Health: National findings , 2009 .

[9]  J. Jaffe,et al.  Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate‐day administration and abrupt withdrawal , 1990, Clinical pharmacology and therapeutics.

[10]  E. Boyer,et al.  Adverse Effects in Children After Unintentional Buprenorphine Exposure , 2006, Pediatrics.

[11]  S. Strathdee,et al.  HIV, Hepatitis C, and Hepatitis B Infections and Associated Risk Behavior in Injection Drug Users, Kabul, Afghanistan , 2007, Emerging infectious diseases.

[12]  R. Dart,et al.  The underrecognized toll of prescription opioid abuse on young children. , 2009, Annals of emergency medicine.

[13]  David E. Smith,et al.  Buprenorphine: blending practice and research. , 2002, Journal of substance abuse treatment.

[14]  W. H. Morse,et al.  Respiratory effects of opioid full and partial agonists in rhesus monkeys. , 1996, The Journal of pharmacology and experimental therapeutics.

[15]  Thomas R Kosten,et al.  Combating opiate dependence: a comparison among the available pharmacological options , 2004, Expert opinion on pharmacotherapy.

[16]  Declan T. Barry,et al.  Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. , 2008, Journal of substance abuse treatment.

[17]  R. Ferner,et al.  Office-based treatment of opioid-dependent patients. , 2003, The New England journal of medicine.

[18]  M. Carrieri,et al.  Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). , 2007, The International journal on drug policy.

[19]  J. Kaldor,et al.  Impact of a reduction in heroin availability on patterns of drug use, risk behaviour and incidence of hepatitis C virus infection in injecting drug users in New South Wales, Australia. , 2007, Drug and alcohol dependence.

[20]  G. Woody,et al.  Abuse of Buprenorphine in the United States , 2007, Journal of addictive diseases.

[21]  N. Horton,et al.  Overdose after detoxification: a prospective study. , 2007, Drug and alcohol dependence.

[22]  B. Mégarbane,et al.  Does High-Dose Buprenorphine Cause Respiratory Depression? , 2006, Toxicological reviews.

[23]  A. Muñoz,et al.  Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. , 2005, The journal of pain : official journal of the American Pain Society.